Building on IAM’s extensive relationships with the Chinese IP community, including our dedicated Chineselanguage magazine, this unique jurisdictional event is specifically designed for senior IP executives at leading Chinese corporates to come together with their international counterparts to discuss the key issues and challenges they face as they develop, expand and internationalise their IP value creation strategies.
Visit the website
This event gave local corporate IP experts a chance to come together with their global counterparts to network, share knowledge and exchange best practice, make connections and do business. With a packed programme focused on corporate IP best practice and key issues facing the Indian market, this event was a great success.
This dedicated one-day event provided a unique opportunity to meet senior decision makers from across Southeast Asia’s diverse corporate, research and regulatory IP communities, and to discuss IP value creation and strategic IP management from the viewpoint of both international and domestic companies operating in Southeast Asia.
As the only event in the region that focuses on how IP owners can strategically use intellectual property, IPBC Asia’s sessions will explore the complex issues associated with IP value creation, but with a specifically Asian flavour, addressing the challenges faced by the region’s rights holders as they seek to expand their businesses across Asia, and beyond
Patent Law and Policy 2016 is taking place the week after the US presidential election and covers key issues including how patent policy might be shaped by the new Congress and the new Administration; the state of patent litigation in 2016; how four years of inter partes reviews have affected patent assertion strategies; and the view from investors on how the legal and legislative climates impact their investment decisions.
This highly informative, content-driven forum, led by our world-class speaking faculty, will showcase practical solutions to the present-day challenges facing life sciences, pharma and biotech companies, legal practitioners and other key stakeholders.
© Copyright 2003-2016 Globe Business Media Group